New baseline biomarkers in Bionomics cancer trial
03 March, 2015Bionomics (ASX:BNO) has revealed new data from the DisrupTOR-1 trial of its anticancer candidate BNC105 in patients with metastatic renal cancer.
New drug candidate on trial for early-stage Alzheimer's
27 February, 2015 by Susan WilliamsonBiotech company Actinogen Medical (ASX: ACW) is progressing a phase 1 trial on its lead drug candidate, Xanamem, which it is hoped will provide a much-needed new treatment option for people with early-stage Alzheimer's disease.
Prescient nabs two US patents for cancer drug
23 February, 2015 by Dylan Bushell-EmblingPrescient Therapeutics (ASX:PTX) has secured two new US patents for PTX-200, a drug candidate with potential applications in platinum-resistant ovarian and other cancers.
Patrys gets new EU patent for PAT-SM6
20 February, 2015 by Dylan Bushell-EmblingPatrys (ASX:PAB) has secured a third European patent - its ninth globally - covering PAT-SM6, an anticancer candidate with potential applications in a wide range of cancers.
Sirtex profit grows 58% in 1H15
18 February, 2015 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has reported a 58.1% increase in net profit for the first half of FY15 as a result of stronger sales of its SIR-Spheres microspheres.
Medvet licenses cell line for cancer antibody
17 February, 2015 by Dylan Bushell-EmblingMedvet Science has licensed the XL-99 cell line from ACYTE Biotech and plans to use the line for the development of a monoclonal antibody with applications in cancer diagnostics and treatment.
New head for NHMRC
11 February, 2015Immunologist and virologist Professor Anne Kelso AO has been appointed as the new chief executive officer of the National Health and Medical Research Council (NHMRC) and will take up the position in April.
Prescient acquires cancer biomarker p27
09 February, 2015 by Dylan Bushell-EmblingPrescient (ASX:PTX) has acquired the exclusive global rights to the p27 biomarker and plans to develop it as a companion diagnostic to cancer drug candidate PTX-100.
Patrys multiple melanoma trial faces delays
06 February, 2015 by Dylan Bushell-EmblingPatrys (ASX:PAB) expects to have to delay a planned trial of PAT-SM6 in multiple myeloma due to issues surrounding the manufacture of materials for the study.
Sienna Cancer Diagnostics names interim CEO
05 February, 2015 by Dylan Bushell-EmblingSienna Cancer Diagnostics has selected former Immune System Therapeutics CEO Dr Cliff Holloway to serve as interim chief executive while a permanent replacement is found.
Clinical Genomics appoints two new VPs
04 February, 2015 by Dylan Bushell-EmblingClinical Genomics has appointed a new VP for APAC and VP of regulatory affairs as part of a global expansion strategy for its colorectal cancer screening products.
Patrys's PAT-SM6 found safe in myeloma trial
04 February, 2015 by Dylan Bushell-EmblingPatrys's (ASX:PAB) PAT-SM6 anticancer candidate met its primary safety and tolerability endpoints during a phase I/IIa multiple myeloma trial.
Novogen on track to regaining Nasdaq compliance
03 February, 2015 by Dylan Bushell-EmblingNovogen (ASX:NRT) has completed placements to ensure it regains compliance with Nasdaq listing rules, while CEO Dr Graham Kelly prepares to present at two investor conferences over the next two weeks.
Goodnow joins Garvan as deputy director
02 February, 2015Professor Chris Goodnow has taken up the position of deputy director at the Garvan Institute of Medical Research.
GTG secures new BREVAGen contracts
30 January, 2015 by Dylan Bushell-EmblingShares in Genetic Technologies (ASX:GTG) more than doubled after the company revealed that up to six new breast centres will stock its BREVAGen breast cancer risk test in Q1, with more contracts on the way.
